>> GNI Group Ltd. 


GNI Group is headquartered in Tokyo, Japan and listed on the Tokyo Stock Exchange, with its major drug discovery and clinical research teams in Shanghai, China and GMP manufacture facility in Beijing, China. The unique business model of GNI Group is to utilize the cost-effective and abundant clinical resources in China as our competitive strength to conduct proof-of-concept Phase I and II clinical trials in China, and then expand to US, Europe, Japan and other global markets.  


 
© 2007~2018 shanghaigenomics.com. All rights reserved. Shanghai ICP 08017875